Navigation Links
Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
Date:3/16/2009

Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio

NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small molecule that selectively inhibits the activation of all three isoforms of Akt. Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation, survival and invasiveness

Co-inventors are Jin Q. Cheng, M.D., Ph.D. and Said M. Sebti, Ph.D. from Moffitt. "This small molecule is a highly selective and potent inhibitor of Akt activation, leading to tumor growth arrest and induction of cancer cell death, and results in overcoming chemoresistance," said Dr. Cheng, Professor, Molecular Oncology Department at Moffitt. "Patients whose tumors contain persistently activated Akt are predicted to be more likely to respond to this inhibitor either as a single agent or in combination therapy," said Dr Sebti, Professor and Chair, Drug Discovery Department at Moffitt. "Akt is abnormally hyperactivated in many advanced malignancies and late stage tumors, such as breast, prostate, lung, pancreatic, liver, ovarian and colorectal cancers. Increased activation is also linked with drug and radiation resistance," said Dr. Cheng.

Through this license, Lyndor plans to develop and commercialize the new anti-cancer agent, which it refers to as LD-101, for refractory and resistant tumors as well as metastatic malignancies, addressing a huge unmet medical need. "Given time, most cancers will relapse, become resistant and, ultimately, refractory. In fact, most become metastatic before detection," said Susan Rosenbaum, Esq., Chairman and CEO of Samtheo. "Lyndor's agreement with Moffitt will enable Lyndor to develop this targeted therapeutic for personalized medicine in the treatment of patients with these difficult-to-treat diseases." Under the license agreement, Lyndor has agreed to pay Moffitt when various milestones are reached and provide Moffitt with running royalties on the sales of licensed products.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center (www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control.

About Lyndor

Lyndor is a privately-held subsidiary of Samtheo that acquired the exclusive, world-wide rights to its lead compound, LD-101, from Moffitt. Lyndor's interest in the treatment of cancer and development of LD-101 as an effective targeted therapeutic agent for personalized medicine is propelled by the desire to improve cancer treatment, offer patients greater life expectancy and provide a better quality of life.

About Samtheo

Samtheo is a privately-held company that invests in biotechnology companies focused on the delivery of personalized medicine through targeted therapeutics. Samtheo is in the business of acquisition, development and commercialization of innovative technology "with integrity", i.e., proprietary, novel intellectual property that will generate evidence-based, medically-effective and socially-assessable products. Samtheo's global mission is to improve health care and outcomes dramatically for patients with life-threatening diseases and unmet medical needs. Samtheo's press releases and other company information are available at www.samtheo.com.


'/>"/>
SOURCE Samtheo Biopharma LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):